United States · Biotechnology startup
United States · Nurix Therapeutics
Nurix Therapeutics is a biopharmaceutical company that focuses on the development and discovery of small molecule drugs.
Funding reportedLast round: Post ipo equity
What company datasets say Nurix Therapeutics raised
Funding, as reported
Reported in all$546Min dollars
Rounds8
Last roundPost ipo equity
Last round dateApr 2024
Investors listed8
SEC Form D$148M sold, 6 filings, last Mar 2020
Founders and team
From Nurix Therapeutics's own website and the SEC filings it signed: 9 on the team.
- John NorthcottChief Commercial Officer
- Wes BurwellChief Human Resources Officer
- Hans van HouteChief Financial Officer
- Anil KapurBoard Director
- Edward C. SaltzmanBoard Director
- Paul M. SilvaBoard Director
- Arthur SandsExecutive Officer, Directori
- Christine RingExecutive Officeri
- Julia P. GregoryChair
On the board, as filediDavid LaceyJeff TongLeon ChenLori KunkelRobert Tjian
Biotechnology in United States
Startups like it
- SojournixWaltham · founded 2016Raised
- Receptor Life SciencesSeattle · founded 2017Raised
- Attune PharmaceuticalsNew York · founded 2018Raised
AbbVieNorth Chicago · founded 2012
GrailMenlo Park · founded 2015
EQRxCambridge · founded 2019- Cerevel TherapeuticsBoston · founded 2018
Royalty PharmaNew York · founded 1996
Is this your company?
Add your raise, your deck and your story, and put Nurix Therapeutics in front of investors. Or tell us what we have wrong.